MedPath

A randomised, controlled trial of exit site application of MedihoneyTM Antibacterial Wound Gel for the prevention of catheter-associated infections in peritoneal dialysis patients, The HONEYPOT Study

Phase 3
Completed
Conditions
Peritoneal dialysis
Chronic renal failure
Renal and Urogenital - Kidney disease
Alternative and Complementary Medicine - Other alternative and complementary medicine
Registration Number
ACTRN12607000537459
Lead Sponsor
Australasian Kidney Trials Network
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
371
Inclusion Criteria

Receiving peritoneal dialysis.
Able to give informed consent.

Exclusion Criteria

Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study. Recent (within 1 month) exit site infection, peritonitis, or tunnel infection. Known hypersensitivity to, or intolerance of, honey or mupirocin. On long term antibiotics. Nasal carriage of mupirocin resistant Staphylococcus aureus.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to first episode of exit site infection, tunnel infection or peritonitis (whichever comes first)[Time from study entry]
Secondary Outcome Measures
NameTimeMethod
Costs[Assessed throughout the study period];Time to first episode of peritonitis[Time from study entry];Time to first tunnel infection[Time from study entry];Time to first exit site infection[Time from study entry];Time to infection-associated catheter removal[Time from study entry];Catheter-associated infection rates[Assessed throughout the study period];Occurrence of mupirocin-resistant microbial isolates[Assessed throughout the study period];Incidence of adverse reactions[Assessed throughout the study period]
© Copyright 2025. All Rights Reserved by MedPath